Please use this identifier to cite or link to this item:
http://dspace.bits-pilani.ac.in:8080/jspui/xmlui/handle/123456789/13304
Title: | Recent trends and spotlight on nucleotide-based drugs: novel targets, their design, delivery, and clinical potential |
Authors: | Jadhav, Hemant R. |
Keywords: | Pharmacy Oligonucleotide therapeutics (OT) Drugs Oligonucleotide therapy Antisense Oligonucleotides (ASOs) Small Interfering RNAs (siRNAs) |
Issue Date: | 2023 |
Publisher: | Frontiers |
Abstract: | Therapeutics comprising of nucleotide entities is very broad class, covers nucleotide analogs, oligonucleotides and nucleic acid-based based therapeutic. Nucleotide/nucleoside-based drugs are already very well explored, with clinically approved candidates as antiviral, anti-cancer, anti-bacterial and anti-rheumatoid etc (Garner, 2021). Oligonucleotide therapy is relative recent and promising, comprising of Antisense Oligonucleotides (ASOs), Small Interfering RNAs (siRNAs), Short Hairpin RNAs (shRNAs), Anti-MicroRNAs (anti-miRs). Oligonucleotides selectively bind to RNA or proteins, blocking their function or promoting degradation. Oligonucleotide therapy shows potential in treating genetic disorders, cancer, viral infections, and neurodegenerative conditions |
URI: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374295/ http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13304 |
Appears in Collections: | Department of Pharmacy |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.